MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

MC

577

-0.1%↓

SANES

6.3

-0.14%↓

BNP

76.85

-1.61%↓

CS.FR

40.35

+1.38%↑

ALV

356.3

+0.45%↑

Search

Bayer AG

Atidarymo kaina

SektoriusFinansų sektorius

21.455 -4.92

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.16

Max

22.575

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.9B

-328M

Pardavimai

1.8B

12B

P/E

Sektoriaus vid.

30.9

22.015

Pelnas, tenkantis vienai akcijai

1.05

Dividendų pajamingumas

0.49

Pelno marža

-2.796

Darbuotojai

90,587

EBITDA

615M

1.7B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+20.47% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.49%

3.90%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

422M

22B

Ankstesnė atidarymo kaina

26.38

Ankstesnė uždarymo kaina

21.455

Naujienos nuotaikos

By Acuity

31%

69%

96 / 542 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Bayer AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-03-24 09:37; UTC

Pagrindinės rinkos jėgos

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

2025-03-05 11:21; UTC

Uždarbis

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

2025-03-05 08:45; UTC

Uždarbis

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

2025-03-05 07:26; UTC

Uždarbis

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2025-03-10 08:38; UTC

Rinkos pokalbiai

Bayer's Partial Recovery Is in Sight -- Market Talk

2025-03-05 13:39; UTC

Rinkos pokalbiai
Uždarbis

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

2025-03-05 13:26; UTC

Rinkos pokalbiai

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

2025-03-05 08:30; UTC

Rinkos pokalbiai
Uždarbis

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

2025-03-05 06:41; UTC

Uždarbis

Bayer Launches Plan to Boost Profitability at Crop Science

2025-03-05 06:40; UTC

Uždarbis

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

2025-03-05 06:39; UTC

Uždarbis

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

2025-03-05 06:39; UTC

Uždarbis

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

2025-03-05 06:36; UTC

Uždarbis

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

2025-03-05 06:35; UTC

Uždarbis

Bayer Guidance is on a Currency Adjusted Basis

2025-03-05 06:34; UTC

Uždarbis

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

2025-03-05 06:34; UTC

Uždarbis

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

2025-03-05 06:33; UTC

Uždarbis

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

2025-03-05 06:33; UTC

Uždarbis

Bayer Sees 2025 Sales EUR45B-EUR47B

2025-03-05 06:32; UTC

Uždarbis

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

2025-03-05 06:31; UTC

Uždarbis

Bayer: Analysts Saw 4Q Net Profit at EUR463M

2025-03-05 06:31; UTC

Uždarbis

Bayer 4Q Net Loss EUR335M

2025-03-05 06:31; UTC

Uždarbis

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

2025-03-05 06:31; UTC

Uždarbis

Bayer 4Q Ebitda Before Special Items EUR2.35B

2025-03-05 06:31; UTC

Uždarbis

Bayer: Analysts Saw 4Q Sales at EUR11.26B

2025-03-05 06:31; UTC

Uždarbis

Bayer 4Q Sales EUR11.73B

2025-01-13 21:05; UTC

Svarbiausios naujienos

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

2025-01-09 15:06; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Didn't Disclose Financial Details

2025-01-09 15:05; UTC

Įsigijimai, susijungimai, perėmimai

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

2025-01-09 15:05; UTC

Įsigijimai, susijungimai, perėmimai

Bayer: Camelina Is Novel Intermediate Oilseed Crop

2025-01-09 15:04; UTC

Įsigijimai, susijungimai, perėmimai

Bayer: Smart Earth Camelina Is Headquartered in Saskatoon, Saskatchewan, Canada

Akcijų palyginimas

Kainos pokytis

Bayer AG Prognozė

Kainos tikslas

By TipRanks

20.47% į viršų

12 mėnesių prognozė

Vidutinis 26.89 EUR  20.47%

Aukščiausias 33 EUR

Žemiausias 22 EUR

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Bayer AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

10 ratings

1

Pirkti

9

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

21.95 / 22.575Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

96 / 542 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.